The DOI matches its Crossref record; the references it cites are not checked yet; 17 of the 119 sources its claims cite were checked for support.
The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review
Open accessAbstract
Brain imaging techniques enable the visualization of serotonin transporter (SERT) occupancy as a measure of the proportion of SERT blocked by an antidepressant at a given dose. We aimed to systematically review the evidence on the relationship between antidepressant dose and SERT occupancy. We searched PubMed and Embase (last search 20 May 2021) for human in vivo, within-subject PET, or SPECT studies measuring SERT occupancy at any dose of any antidepressant with highly selective radioligands ([ 11 C]-DASB, [ 123 I]-ADAM, and [ 11 C]-MADAM). We summarized and visualized the dose-occupancy relationship for antidepressants across studies, overlaying the plots with a curve based on predicted values of a standard 2-parameter Michaelis–Menten model fitted using the observed data. We included seventeen studies of 10 different SSRIs, SNRIs, and serotonin modulators comprising a total of 294 participants, involving 309 unique occupancy measures. Overall, following the Michaelis–Menten equation, SERT occupancy increased with a higher dose in a hyperbolic relationship, with occupancy increasing rapidly at lower doses and reaching a plateau at approximately 80% at the usual minimum recommended dose. All the studies were small, only a few investigated the same antidepressant, dose, and brain region, and few reported information on factors that may influence SERT occupancy. The hyperbolic dose-occupancy relationship may provide mechanistic insight of relevance to the limited clinical benefit of dose-escalation in antidepressant treatment and the potential emergence of withdrawal symptoms. The evidence is limited by non-transparent reporting, lack of standardized methods, small sample sizes, and short treatment duration. Future studies should standardize the imaging and reporting procedures, measure occupancy at lower antidepressant doses, and investigate the moderators of the dose-occupancy relationship.
Overview
CoChat Summary
TL;DR
This systematic review of within-subject PET/SPECT studies found that antidepressant dose and serotonin transporter (SERT) occupancy follow a hyperbolic relationship, with occupancy rising steeply at low doses and plateauing at approximately 80% at the usual minimum recommended dose. The authors suggest this may help explain the limited clinical benefit of dose escalation and the emergence of withdrawal symptoms during tapering.
Key findings
- Across 17 studies, 10 antidepressants, 294 participants, and 309 unique occupancy measures, SERT occupancy increased hyperbolically with dose and reached an apparent plateau of approximately 80% at roughly the usual minimum recommended dose for depression.
- Reported ED50 values in mg were 3.4 for citalopram, 9.1 for sertraline, 5 for paroxetine, 2.7 for fluoxetine, 5.8 for venlafaxine, 7.9 for duloxetine, 8.5 for vortioxetine, and 14.4 for desvenlafaxine.
- Three studies measuring occupancy after single and repeated dosing found higher occupancy after repeated dosing: duloxetine 20 mg increased from 65% to 78% after 4 days; citalopram 20 mg and escitalopram 10 mg increased from 73% and 74% to 80% and 77% after 25 days; vortioxetine 2.5, 10, and 60 mg increased from 27%, 44%, and 70% to 35%, 63%, and 93% after 9 days.
- For escitalopram, citalopram, and sertraline, but not paroxetine and fluvoxamine, SERT occupancy appeared to decrease more slowly than plasma concentration over time.
Methods
- Systematic review registered at Open Science Framework and reported per PRISMA; searched PubMed and Embase (last search 20 May 2021) for human in vivo within-subject PET or SPECT studies measuring SERT occupancy at any dose of any approved oral antidepressant.
- Included studies used highly selective radioligands [11C]-DASB, [123I]-ADAM, or [11C]-MADAM; 16 articles reporting 17 unique studies were included after screening 793 abstracts and 100 full texts.
- Data were extracted independently by two researchers; because meta-analysis was not meaningful, occupancy was presented by dose, drug, and brain region as means and SDs, and dose-occupancy relationships were visualized with a fitted 2-parameter Michaelis–Menten model for antidepressants administered at four or more doses.
Limitations
- The authors state that studies were small, few investigated the same antidepressant, dose, and brain region, and few reported factors influencing SERT occupancy; evidence is limited by non-transparent reporting, lack of standardized methods, small sample sizes, and short treatment duration.
- The authors also note that different reference tissue models were combined, brain-region comparisons may not be clinically meaningful, the search may have missed studies due to inconsistent nomenclature, fitted curves did not consider individual study sample sizes, dose ranges were limited for some drugs, single- and repeated-dosing regimens could not be stratified, and co-medication effects could not be explored.
- Evident from the text: most included studies investigated healthy individuals aged roughly 25–40 years, most were male, and some doses were investigated in only one to three participants, limiting generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
12 Valid · 1 Not valid · 30 Not checked · 55 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“such strategies may, however, also largely be ineffective [4–7].”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Introduction
What the sources say
- Partly supportedcites [4] Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 2019;6:601–9. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports no further efficacy gain from increasing SSRI or mirtazapine doses beyond approximately 20–40 mg fluoxetine equivalents. That supports the claim if “such strategies” means further dose escalation, but the paper also finds benefits from increases up to that range and a possible slight gain at higher venlafaxine doses. It does not support calling treatment strategies broadly ineffective. (LLM, conf=0.78)
- Supportedcites [5] Braun C, Adams A, Rink L, Bschor T, Kuhr K, Baethge C. In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Acta Psychiatr Scand 2020;142:430–42. source
The paper’s discussion (section ‘This analysis revealed three important results: (i)’, page unavailable) finds negligible benefit from raising SSRI doses from medium to high levels and describes dose increases as generally unpromising for nonresponders. This supports the hedged claim insofar as ‘such strategies’ refers to SSRI dose escalation; the paper does not rule out a benefit in individual cases. (LLM, conf=0.88)
- Not checked yetcites [6] Rink L, Braun C, Bschor T, Henssler J, Franklin J, Baethge C. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry. 2018;79:17r11693. https://doi.org/10.4088/JCP.17r11693. source
- Not checked yetcites [7] Bschor T, Kern H, Henssler J, Baethge C. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry. 2018;79:16r10749. https://doi.org/10.4088/JCP.16r10749. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The efficacy of antidepressant treatment for depression is modest compared with placebo [2, 3]”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Introduction
What the sources say
- Partly supportedcites [2] Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open 2019;9:e024886. sourceExperimental — accuracy not yet measured
The Discussion says the reported antidepressant effect over placebo on depression rating scales was small, supporting the description of a modest measured effect. But the Discussion and Abstract Conclusions caution that the evidence does not establish whether antidepressants are more efficacious than placebo; the claim presents modest efficacy more definitively than the paper does. (LLM, conf=0.87)
- Supportedcites [3] Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357–66. source
The Discussion states that all included antidepressants were more efficacious than placebo in adults with major depressive disorder, while their summary effect sizes were mostly modest. This directly supports the citing sentence for the acute treatment studied. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Common treatment strategies in patients with depression for whom antidepressant treatment has not been effective include increasing the antidepressant dose or switching to a different antidepressant”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Introduction
What the sources say
- Partly supportedcites [4] Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 2019;6:601–9. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports an APA guideline recommending that antidepressant doses be raised as tolerated, supporting dose increases as a treatment strategy. It does not say this is a common response to ineffective treatment, and the passages found do not identify switching to another antidepressant as such a strategy. (LLM, conf=0.80)
- Partly supportedcites [5] Braun C, Adams A, Rink L, Bschor T, Kuhr K, Baethge C. In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Acta Psychiatr Scand 2020;142:430–42. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says SSRI doses are often increased during treatment, and the Inclusion criteria (page unavailable) describe dose increases as second-step strategies after non-response. The passages do not identify switching to a different antidepressant as a common strategy after treatment failure. (LLM, conf=0.85)
- Not checked yetcites [6] Rink L, Braun C, Bschor T, Henssler J, Franklin J, Baethge C. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry. 2018;79:17r11693. https://doi.org/10.4088/JCP.17r11693. source
- Not checked yetcites [7] Bschor T, Kern H, Henssler J, Baethge C. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry. 2018;79:16r10749. https://doi.org/10.4088/JCP.16r10749. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Given the paucity of evidence for specific tapering regimens [13, 14]”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Introduction
What the sources say
- Supportedcites [13] Maund E, Stuart B, Moore M, Dowrick C, Geraghty AWA, Dawson S, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med 2019;17:52–60. source
In “Strengths and Limitations” (page unavailable), the review says that more trials of slower tapering are needed and notes an ongoing comparison of one-week and two-week tapers. This supports the claim that evidence for specific tapering regimens is scarce. (LLM, conf=0.91)
- Not checked yetcites [14] Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021;4:CD013495.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“a total of 16 articles (reporting on 17 unique studies) were included [17–19, 28–40].”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Results
What the sources say
- Not checked yetcites [17] Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826–35. source
- Not checked yetcites [18] Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacol (Berl) 2006;188:263–72. source
- Supportedcites [19] Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 2007;10:777–85. source
The Subjects and design section describes an original PET study involving nine healthy male subjects. In this citation list, the source identifies one of the studies included by the citing authors; the total of 16 articles and 17 studies is the citing authors’ own count, not a count attributed to this individual paper. (LLM, conf=0.88)
- Supportedcites [28] Abanades S, van der Aart J, Barletta JAR, Marzano C, Searle GE, Salinas CA, et al. Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 2011;31:944–52. source
The Materials and methods describe an open-label study in healthy adult males, and the Results report its participants and findings. As one citation in a list of included articles, this paper supports its identification as an included study; the aggregate count of 16 articles and 17 studies is the citing authors’ tally, not a result attributed to this individual paper. (LLM, conf=0.85)
- Not checked yetcites [29] Areberg J, Mahableshwarkar A, Sanchez C. Vortioxetine: exploratory analysis of the relation between target engagement and integrated clinical database analysis of MADRS single items. Int J Neuropsychopharmacol 2014;17:58.
- Not checked yetcites [30] Arakawa R, Tateno A, Kim W, Sakayori T, Ogawa K, Okubo Y. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: a positron emission tomography study with [(11)C]DASB. Psychiatry Res Neuroimaging 2016;251:1–6. source
- Not checked yetcites [31] Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, et al. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. Neuroimage 2014;88:252–62. source
- Not checked yetcites [32] Catafau AM, Perez V, Plaza P, Pascual J-C, Bullich S, Suarez M, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacol (Berl) 2006;189:145–53. source
- Not checked yetcites [33] Frankle WG, Robertson B, Maier G, Paris J, Asmonga D, May M, et al. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine. Synapse. 2018;72. https://doi.org/10.1002/syn.22021. source
- Not checked yetcites [34] Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: Initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 2000;27:1719–22. source
plainn = 16- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 102 references still open.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 37
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This has been suggested to be the case for antidepressants when tapering using standard available doses, especially for the last reductions before cessation due to the large biological effects even at very low and subtherapeutic doses.12,16,49”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the absence of RCTs, tapering guidance could be informed by other types of evidence such as non-randomised and retrospective studies of tapering strips,17,18 pharmacologically rational theory on withdrawal symptoms and dose-reduction regimens,12,49 patients’ experiences of undergoing withdrawal, 50 and expert knowledge, 51 which could be synthesised for that purpose.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [49]
In the citing paper
“This could be because we used a high daily dose of 20 mg escitalopram, which we expected to lead to a near-maximum occupancy of 70–80% of the serotonin transporter [47].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Results
“| Takano et al. (2006a) [39] | Flv | 6 | 6 | 50 | DASB | 5 + 26 + 53 | 1 | 24.3 ± 4.8 | Healthy | FC, tha, str, hip, amy | MRTM2 |”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Results
“| | | FC (6) | 75 ± 9 | 28 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Results
“| 40 (17, 34, 38)a | 6 | overall | 80 ± 5–85 ± 4 | |”
§ The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review > Results
“| | | str (8) | 73 ± 6–85 ± 4 | 56–70, 28 |”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 62 · Cited by 65
Research works printed but not linked: 2
- Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86–102.
- Areberg J, Mahableshwarkar A, Sanchez C. Vortioxetine: exploratory analysis of the relation between target engagement and integrated clinical database analysis of MADRS single items. Int J Neuropsychopharmacol 2014;17:58.
Metadata
- Authors
- Sørensen, A., Ruhé, H. G., & Munkholm, K.
- Affiliations
- Rigshospitalet (DK)
- Radboud University Nijmegen (NL)
- University of Southern Denmark (DK)
- Corresponding author
- Sørensen, Anders
- Venue
- Molecular Psychiatry
- Published
- 2021-09-21
- Volume
- 27
- Issue
- 1
- Pages
- 192-201
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8960396
- OpenAlex
- W3199137132
- Cited by
- 65
- References
- 62
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 13 · 2023: 13 · 2022: 11
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antidepressants, Michaelis-Menten model, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, PET radiotracer, [11C]DASB, antidepressant withdrawal symptoms
- MeSH terms
- Antidepressive Agents, Brain, Humans, Citalopram, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. https://app.cochat.ai/papers/10.1038/s41380-021-01285-w
- The paper
- Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022). The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01285-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.